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Background: Fibroblasts are indispensable for the fabrication of cell-sheetebased bioengineered cardiac
tissues; however, whether cardiac ﬁbroblasts can improve tissue properties for transplantation or in vitro
models compared with other ﬁbroblast types remains unclear. We compared the cell organization and
functional properties of cardiomyocyte sheets derived from co-culture with different ﬁbroblast types and
investigated the molecular mechanisms for the observed differences.
Methods and results: Cardiac cell sheets were fabricated by co-culturing mouse embryonic stem cell
(ESC)-derived cardiomyocytes with mouse neonatal cardiac ﬁbroblasts (NCFs), mouse adult cardiac ﬁ-
broblasts (ACFs), and mouse adult dermal ﬁbroblasts (ADFs). Cardiac cell sheets obtained from NCF or
ACF co-culture showed numerous uniformly distributed and functional (beating) cardiomyocytes, while
cell sheets obtained by co-culture with ADFs showed fewer and aggregated cardiomyocytes. The greater
number of cardiomyocytes in the presence of NCFs was because of enhanced cardiomyocyte prolifera-
tion, as revealed by protein markers of mitosis and BrdU incorporation. Microarray analysis revealed that
NCFs expressed substantially higher levels of vascular cell adhesion molecule-1 (VCAM-1) than ADFs.
Treatment of ESC-derived cardiomyocytes in monoculture with soluble VCAM-1 signiﬁcantly increased
the number of functional cardiomyocytes, while the enhancement of cardiomyocyte number by co-
culture with NCFs was abolished by anti-VCAM-1 antibodies.
Conclusions: Cardiac ﬁbroblasts enhance the proliferation of ESC-derived cardiomyocytes through
VCAM-1 signaling, leading to an increase in functional myocardial cells in bioengineered tissue sheets.
These sheets may be advantageous for cell-based therapy and in vitro heart research.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Fibroblasts exist in almost all vertebrates, where they form and
stabilize the three-dimensional structure of tissues by secreting
extracellular matrix components. Fibroblasts respond to tissue
injury and ischemia by proliferating and depositing new extracel-
lular matrix to aid in repair [1]. However, severe injury may result
in excessive ﬁbroblast proliferation, resulting in ﬁbrosis and-Ku, Tokyo 162-8666, Japan.
se Society for Regenerative
es, Keio University.
ative Medicine. Production and hoconcomitant loss of tissue function. Myocardial infarction and
cardiomyopathies can result in cardiomyocyte loss, creating voids
that are ﬁlled by ﬁbrous tissue; this ﬁbrosis can lead to cardiac
remodeling and heart failure [2]. Cardiac ﬁbroblasts secrete
neurohumoral factors such as angiotensin II and endothelin-1
which are known to contribute to cardiac remodeling via blood
pressure elevation, cardiomyocyte apoptosis, and local inﬂamma-
tion [3].
During development, cardiac ﬁbroblasts form a network of cell
processes and collagen ﬁbers to guide myocyte organization. Fi-
broblasts promote embryonic cardiomyocyte proliferation, an
indispensable process for forming thick ventricular walls, through
b1 integrin signaling [4]. However, the identity of the cardiac
ﬁbroblast-derived promitotic factor remains unclear. Moreover,
cell-cell interactions between cardiac ﬁbroblasts and embryonicsting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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ogenesis have not been elucidated in detail.
Mechanisms of myocyteﬁbroblast signaling are important
not only for understanding heart development and pathogenesis
but also for heart tissue engineering. We are developing a cell-
sheetebased cardiac tissue engineering method using
temperature-responsive culture dishes. Layering cardiac cell sheets
containing neonatal rat-derived cardiomyocytes, ﬁbroblasts, and
endothelial cells on vascular beds enables the fabrication of viable,
vascularized cardiac tissue [5e7]. This cell-sheetebased tissue en-
gineering does not require a scaffold but requires an extracellular
matrix. Thus, the presence of ﬁbroblasts is indispensable for
fabrication of cardiac cell sheets from puriﬁed embryonic stem cell
(ESC)-derived cardiomyocytes [8]. Recent reports have suggested
that cellecell interactions between cardiomyocytes and non-
myocytes, such as cardiac ﬁbroblasts, are important for heart
physiology and repair [9]. Thus, use of cardiac ﬁbroblasts may
improve the fabrication of cardiac tissue for transplantation and
in vitro studies. However, whether cardiac ﬁbroblasts have a spe-
ciﬁc development function or are interchangeable with ﬁbroblasts
from other tissues for cardiomyocyte proliferation and function
remains unclear.
Here we demonstrate that cardiac ﬁbroblasts, but not dermal
ﬁbroblasts, promote the proliferation of mouse ESC-derived car-
diomyocytes and facilitate the development of functional cardiac
cell sheets. Cardiac ﬁbroblasts expressed higher levels of VCAM-1
than dermal ﬁbroblasts. We show that release of VCAM-1 from
cardiac ﬁbroblasts facilitates cardiac myocyte proliferation and
distribution of functional (contracting) cardiomyocytes in bio-
engineered cardiac tissue sheets.
2. Methods
2.1. Animals and reagents
This study was carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory Animals
of Tokyo Women's Medical University. All experimental protocols
were approved by the Institutional animal care and use committee
of Tokyo Women's Medical University. All efforts were made to
minimize suffering. Wild-type C57BL/6 mice were purchased from
Japan SLC (Shizuoka, Japan) and B6 Cg-Tg (CAG-DsRed*MST) 1Nagy/
J mice from The Jackson Laboratory (Bar Harbor, ME).
The following antibodies were used for immunocytochemistry,
enzyme-linked Immunosorbent assay (ELISA), and ﬂow cytometry:
rabbit polyclonal anti-discoidin domain receptor tyrosine kinase 2
(DDR2) (GeneTex, Irvine, CA), guinea pig monoclonal anti-vimentin
(Progen, Heidelberg, Germany), mouse monoclonal anti-NG2
(Millipore, Temecula, CA), rabbit polyclonal anti-alpha smooth
muscle actin (aSMA) (Abcam, Cambridge, UK), mouse monoclonal
anti-cardiac troponin T (cTnT) (Thermo Scientiﬁc, Rockford, IL),
mouse monoclonal anti-cytokeratin11 (EXBIO, Nad Saﬁnou, CZ),
rabbit polyclonal anti-Ki67 (Abcam), rabbit polyclonal anti-
phospho-histone H3 (phospho S10) (Abcam), rat monoclonal
anti-integrin a4b1 (Abcam), and recombinant mouse VCAM-1/
CD106 Fc chimera (R&D Systems, Minneapolis, MN). Secondary
antibodies against guinea pig, mouse, rabbit, and rat were pur-
chased from Jackson ImmunoResearch Laboratories (West Grove,
PA). Unless otherwise speciﬁed, all reagents were purchased from
SigmaeAldrich (St. Louis, MI).
2.2. Mouse embryonic stem cell cultures
The methods for isolation and maintenance of mouse ESC
(mESC)-derived cardiomyocytes expressing yellow ﬂuorescentprotein (YFP) and the neomycin phosphotransferase gene under
control of the a-myosin heavy chain promoter were described
previously [8]. In that study, we reported that more than 99% of
cells were positive for myosin heavy chain, about 98% for sarco-
meric a-actinin, and about 85% for cardiac troponin T (cTnT).
2.3. Fibroblast isolation
Fibroblasts were obtained from 1 day old (neonatal) and 10e12
weeks old (adult) wild-type C57BL/6 mice as described previously
[8]. Neonatal cardiac ﬁbroblasts (NCFs) were used for experiments
after the third passage. Adult cardiac ﬁbroblasts (ACFs) and adult
dermal ﬁbroblasts (ADFs) were obtained using the explant culture
method. For isolation of NCFs and ACFs, fresh mouse hearts (P1 or
10e12 weeks of age, respectively) were washed with phosphate
buffered saline (PBS) and cut into approximately 4 mm2 pieces.
These pieces were covered with sterilized cover glasses and
cultured in DMEM supplemented with 10% FBS on 10 cm diameter
culture dishes. Twoweeks after seeding, cells were dissociatedwith
0.25% trypsin/EDTA and sub-cultured to other 10 cm dishes. ACFs
from passage 3were used for experiments. Adult dermal ﬁbroblasts
(ADFs) were obtained from dorsal dermal tissue of adult mice
(10e12 weeks of age). Harvested dermal tissues were treated with
dispase I (1000 U/mL) (Eidea, Ibaraki, Japan) overnight at 4 C and
then cut into approximately 25 mm2 pieces. These pieces were
covered with sterilized cover glasses and cultured in DMEM sup-
plemented with 10% FBS on 10 cm culture dishes. Two weeks after
seeding, cells were dissociated with 0.25% trypsin/EDTA and sub-
cultured on 10 cm dishes. ADFs from passage 3 were used for the
experiments.
In some experiments, NCFs and ADFs were isolated from CAG-
DsRed*MST 1Nagy/J mice (Neonatal: 1 day, Adult: 10 weeks)
using the same methods.
2.4. Cell sheet preparation
Before seeding cells, temperature-responsive culture dishes
(UpCell; CellSeed, Tokyo, Japan) were incubated with fetal bovine
serum (FBS) for 2 h mESC-derived cardiomyocytes were co-
cultured with each type of ﬁbroblasts at a ratio of 8:2 with
DMEM supplemented with 10% FBS (Fibroblasts ¼ 5.4  104 cells/
cm2; cardiomyocytes ¼ 2.16  105 cells/cm2). After 5 days, co-
cultures were incubated at 20 C to detach the cell sheets. Bright
ﬁeld images of co-cultures were obtained using a Nikon ECLIPSE Ti
microscope (Nikon, Tokyo, Japan).
2.5. Electrophysiological analysis
Extracellular ﬁeld potentials from cardiomyocyte sheets were
measured by a multi-electrode array (MED) system (Alpha MED
Sciences, Osaka, Japan) as described previously [8].
2.6. Immunocytochemistry
Cells were ﬁxed with 4% paraformaldehyde and immunostained
as described [8]. Immunostaining was analyzed using an ImageX-
press Ultra Confocal High Content Screening System and MetaEx-
press software (Molecular Devices, CA).
2.7. Flow cytometry analysis of BrdU incorporation
Cells (5  105 per trial) were incubated in cell culture medium
containing 10 mM BrdU. BrdU staining and analysis were per-
formed according to an instruction manual (BD Pharmingen,
Franklin Lakes, NJ). Cells were ﬁxed and permeabilized with BD
T. Iwamiya et al. / Regenerative Therapy 4 (2016) 92e10294Cytoﬁx/Cytoperm Buffer, then exposed to BrdU in solution with
DNase. BrdU staining was performed with APC-anti-BrdU antibody
(BD Pharmingen, Franklin Lakes, NJ). Samples were analyzed with
a Gallios ﬂuorescence activated cell sorting (FACS) system (Beck-
man Coulter, Brea, CA). The following reagents were used for
analysis: BD Cytoﬁx/Cytoperm Buffer, BD Perm/Wash Buffer (10),
BD Cytoperm Plus Buffer (10), BrdU, and DNase (all from BD
Pharmingen).2.8. Time-lapse photography
Images were acquired over ﬁve days using a BZ-9000 ﬂuores-
cence microscope maintained in humidiﬁed air containing 5% CO2
at 37 C (Keyence, Osaka, Japan).2.9. RNA extraction and microarray analysis
From ﬁbroblasts (NCFs and ADFs), total RNAwas extracted using
TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manu-
facturer's instructions and further puriﬁed using the Qiagen RNeasy
Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's
instructions. RNA quantity and quality were determined using a
Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientiﬁc
Inc., Waltham, MA) and an Agilent Bioanalyzer (Agilent Technolo-
gies) as recommended.
For cRNA ampliﬁcation and labeling, total RNA was ampliﬁed
and labeled with cyanine 3 (Cy3) using Agilent Low Input Quick
Amp Labeling Kit, one-color (Agilent Technologies) following the
manufacturer's instructions. Brieﬂy,100 ng of total RNAwas reverse
transcribed to double-stranded cDNA using a poly dT-T7 promoter
primer. Primer, template RNA, and quality-control transcripts of
known concentration and quality were ﬁrst denatured at 65 C for
10 min and then incubated for 2 h at 40 C with 5  ﬁrst strand
Buffer, 0.1 M DTT, 10 mM dNTP mix, and AfﬁnityScript RNase Block
Mix. The AfﬁnityScript enzyme was inactivated by heating to 70 C
for 15 min cDNA products were then used as templates for in vitro
transcription to generate ﬂuorescent cRNAs. cDNA products were
mixed with a transcription master mix in the presence of T7 RNA
polymerase and Cy3-labeled CTP and incubated at 40 C for 2 h.
Labeled cRNAs were puriﬁed using QIAGEN's RNeasy mini spin
columns and eluted in 30 mL of nuclease-free water. After ampliﬁ-
cation and labeling, cRNA quantity and cyanine incorporation were
determined using a Nanodrop ND-1000 spectrophotometer and an
Agilent Bioanalyzer. For sample hybridization, 1.65 mg of Cy3-
labeled cRNA was fragmented and hybridized to an Agilent
Mouse GE 4  44 K v2 Microarray (Design ID: 026655) at 65 C for
17 h. After washing, microarrays were scanned using an Agilent
DNA microarray scanner.
For analysis of microarrays, intensity values of each scanned
feature were quantiﬁed using Agilent feature extraction software
version 10.7.3.1, which performs background subtraction. We only
used features that were ﬂagged as “no errors” (present ﬂags) and
excluded features that were not positive, not signiﬁcant, not uni-
form, not above background, saturated, or were population out-
liers (marginal and absent ﬂags). Normalization was performed
using Agilent GeneSpring GX version 11.0.2. (per chip: normali-
zation to 75 percentile shift; per gene: normalization to median of
all samples). There are 39,429 probes on the Agilent Mouse GE
4  44 K v2 Microarray (Design ID: 026655) excluding control
probes.
The altered transcripts were quantiﬁed using the comparative
method. We applied a 2-fold change in signal intensity as the
threshold to identify signiﬁcant differences in gene expression
between NCFs and ADFs.2.10. Quantitative real-time PCR analysis
Complementary DNA was generated from total RNA using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA), PCR-related primers, and TaqMan Universal PCR
Master Mix (Applied Biosystems). Each RT-PCR reactionwas run for
10 min at 25 C, 120 min at 37 C, and 5 s at 85 C using an iCycler
(BIO-RAD). A 1-mg sample of cDNAwas used from each run. TaqMan
probe real-time PCR studies were performed with TaqMan Gene
Expression Assays (Applied Biosystems). All experiments were
conducted in triplicate. Samples were cycled 40 times with a 7300
Real Time PCR System (Applied Biosystems) as follows: 2 min at
50 C and 10 min at 95 C, followed by 40 cycles of 15 s at 95 C and
1 min at 60 C. Relative changes in expression were calculated ac-
cording to the DDCT method using GAPDH as the endogenous
control.
2.11. Enzyme-linked immunosorbent assay (ELISA)
NCFs and ADFs were seeded onto 10 cm dishes. After incubation
for 3 days in DMEM supplemented with 10% FBS, cells werewashed
with PBS thoroughly 3 times and medium was changed to serum-
free DMEM. After incubation for 24 h in serum-free medium, su-
pernatant was collected as CM and contaminated cells were
removed using a 0.45-mm ﬁlter (BD Falcon). VCAM-1 release in
culture supernatant was measured by ELISA (R&D systems), ac-
cording to the manufacture's instruction.
2.12. Neutralizing antibody assays
After pretreatment with 10 mg/mL neutralizing antibodies for
30 min, ﬁbroblasts were seeded onto the upper surface of two-
chamber culture dishes at 2.4  105 cells/dish, while mouse ESC-
derived cardiomyocytes were seeded onto the lower surface at
4.8  105 cells/dish. The culture medium containing the antibody
(10 mg/mL) was changed every day for 5 days. The following anti-
bodies and culture dishes were used for neutralizing antibody as-
says: anti-VCAM-1 (LifeSpan Biosciences, Seattle, WA); anti-
integrin a4b1 (Santa Cruz), and goat IgG isotype control (LifeSpan
Biosciences). Cell culture inserts for 24-well plates (0.4 mm pores,
translucent, High Density PET Membrane) were from BD
Pharmingen.
2.13. Statistical analysis
All data are presented as the mean ± SD. A signiﬁcant difference
among multiple means was determined by one-way ANOVA.
TukeyeKramer Multiple Comparison Tests were used for post hoc
pair-wise comparisons. All statistical calculations were performed
using Statcel Software. A p value of <0.05 was considered signiﬁ-
cantly different.
3. Results
3.1. Cell sheet formation using mESC-derived cardiomyocytes and
ﬁbroblasts
The vast majority of cells isolated from neonatal heart, adult
heart, and adult dermal tissue had a ﬁbroblast-like morphology
(Fig. 1). Since there are no speciﬁc antibodies for ﬁbroblasts, we
examined the expression of several proteins known to be
expressed by ﬁbroblasts: DDR2 (CD167b) [10], vimentin [11], and
aSMA [12]. Almost all cells co-expressed DDR2, vimentin, and
aSMA, but not calponin (a smooth muscle cell marker), cytoker-
atin 11 (an epithelial cell marker), or neural/glial antigen 2 (NG2,
Fig. 1. Microscopic characterization of NCFs, ACFs, and ADFs. (A) Bright ﬁeld microscopic images of each ﬁbroblast type (Scale bar ¼ 200 mm). (BeE) Representative images of DDR2,
vimentin, and aSMA immunoﬂuorescence. Almost all ﬁbroblasts were DDR2(þ), vimentin(þ), and aSMA(þ) but negative for calponin, cytokeratin11, and NG2. Scale bar ¼ 500 mm.
T. Iwamiya et al. / Regenerative Therapy 4 (2016) 92e102 95a pericyte marker). From these ﬁndings, we concluded that the
vast majority of isolated cells were ﬁbroblasts (ACFs, NCFs, or
ADFs).
Co-culture of ESC-derived cardiomyocytes with ACFs, NCFs, or
ADFs at 20 C for ﬁve days resulted in the formation of monolayer
cell sheets, while no sheets were formed in the absence of ﬁbro-
blasts (Fig. 2A). When cardiomyocytes were co-cultured with ACFs
or NCFs, beating cardiomyocytes were numerous and equally
distributed over the sheet area (Video 1, Video 2). In contrast,
when cardiomyocytes were co-cultured with ADFs, beating cells
were sparse and aggregated into smaller punctate regions Video 3.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.reth.2016.01.005.
Electrophysiological measurements using a MED system [8,13]
conﬁrmed the microscopic determination of functional (beating)
cardiomyocyte number and distribution (Fig. 2B). Extracellular ac-
tion potentials (APs) were observed from many more electrode
sites in cell sheets derived using ACFs or NCFs co-culture compared
to cell sheets derived using ADFs co-culture.To conﬁrm these differences in cardiomyocyte distribution
among cell sheets, co-cultures of ﬁbroblasts and ESC-derived
myocytes expressing YFP were immunostained and imaged using
confocal microscopy. The number of YFP(þ)/cTnT(þ) cells was
signiﬁcantly higher in cell sheets with ACFs or NCFs than in cell
sheets with ADFs (Fig. 2CeD). In fact, the number of car-
diomyocytes in cell sheets with ADFs was comparable to that in
cultures without ﬁbroblasts (monocultures). There was no signiﬁ-
cant difference in cardiomyocyte number between ACFs-derived
and NCFs-derived cell sheets.
3.2. Cardiomyocyte proliferation in cell sheets
To examine the mechanisms for enhanced cardiomyocyte
number in the presence of cardiac ﬁbroblasts (ACFs and NCFs
compared to ADFs and ﬁbroblast-free cultures), cultures were
examined on Day 1 and Day 5 after seeding (Fig. 3AeB). On Day 1,
the number of cardiomyocytes was identical among co-culture
conditions, suggesting that ﬁbroblast type did not affect the
Fig. 2. Differences in cardiomyocyte number and distribution in cell sheets co-cultured with mouse neonatal cardiac ﬁbroblasts (NCFs), adult cardiac ﬁbroblasts (ACFs), or adult
dermal ﬁbroblasts (ADFs). Mouse embryonic stem cell (ESC)-derived cardiomyocytes were cultured with NCFs, ACFs, or ADFs, or cultured alone (monoculture). (A) Evaluation of
cardiac cell sheet formation with and without each ﬁbroblast type. (B) Extracellular action potentials recorded in cell sheets derived from NCFs, ACFs, and ADFs co-cultures and from
cardiomyocyte monocultures. (Red circles show the edges of the cell sheet). (C) Immunocytochemical analysis of each co-culture system using confocal microscopy; YFP/cTnT
(green), vimentin (red), Hoechst 33258 (blue nuclei), scale bar ¼ 500 mm. (E) Bar graph representing the fold increase in YFP(þ)/cTnT(þ) cell number in each cell culture condition.
The YFP(þ)/cTnT(þ) cell number in ﬁbroblast-free cultures (ﬁbroblast()) was set at 1.0 (N ¼ 3, **P < 0.01).
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with ACFs or NCFs, the number of YFP(þ)/cTnT(þ) car-
diomyocytes on Day 5 was signiﬁcantly higher than on Day 1, while
there was no signiﬁcant increase in cardiomyocytes in co-cultures
with ADFs or in myocyte monocultures. Time-lapse image anal-
ysis of co-cultures containing YFP(þ) cardiomyocytes andﬁbroblasts isolated from DsRed mice (expressing red ﬂuorescent
protein under control of the CAG promoter) showed that car-
diomyocytes migrated, proliferated, and formed an interacting
network with NCFs (Video 4). Conversely, cardiomyocytes showed
less proliferation in co-culture with ADFs and did not construct
such a network (Video 5).
Fig. 3. Changes in cardiomyocyte number from Day 1 to Day 5 in each culture condition. (A) Immocytochemical analysis of cell numbers under each cell condition on Day 1 and Day
5; YFP (green), cTnT (red), Hoechst 33258 (blue nuclei), scale bar ¼ 500 mm. (B) Number of cardiomyocytes/culture. Bar graphs depict the fold increase in YFP(þ)/cTnT(þ) cells. The
value for ﬁbroblasts() cultures on Day1 is set at 1.0 (N ¼ 3, **P < 0.01). (CeD) Staining for cell proliferation markers Ki67 and Phh3 cardiomyocytes under each culture condition;
cTnT (green), Ki67/Phh3 (red), and Hoechst 33258 (blue nuclei), scale bar ¼ 500 mm (N ¼ 4, **P < 0.01).
T. Iwamiya et al. / Regenerative Therapy 4 (2016) 92e102 97Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.reth.2016.01.005.
The differential proliferation of cardiomyocytes among co-
culture conditions was conﬁrmed by immunocytochemical anal-
ysis. The percentage of YFP(þ) cardiomyocytes expressing the
mitotic markers Ki67 and phospho-histone H3 (Phh3) was signiﬁ-
cantly higher in co-cultures with NCFs than in co-cultures with
ADFs or in myocyte monocultures (Fig. 3CeD). BrdU incorporation
by cardiomyocytes was signiﬁcantly higher in co-culture with NCFs
compared to co-culture with ADFs or in myocyte monocultures
(Fig. 4AeB).
To investigate the underlying mechanisms for enhanced car-
diomyocyte proliferation in the presence of NCFs, mESC-derived
cardiomyocytes and NCFs were cultured in separate chambers,
with NCFs on the upper layer and cardiomyocytes on the lower
layer, to distinguish the contribution of cellcell contact from
extracellular signaling by soluble factors (Fig. 4C). The number of
cardiomyocytes on Day 5 was still markedly higher than that on
Day 1 (Fig 4D), although the magnitude of the increase (~1.5 folds)
was lower than that in co-culture with direct cellcell contact (~2.5times) (Fig. 4E). These ﬁndings suggest that both soluble factors
secreted from NCFs and direct cellcell interactions between car-
diomyocytes and cardiac ﬁbroblasts promote cardiomyocyte
proliferation.
3.3. Identiﬁcation of ﬁbroblastcardiomyocyte signaling factors by
comparative analysis of ﬁbroblasts gene expression
To identify the factors responsible for enhanced cardiomyocyte
proliferation secreted by NCFs, we performed a comprehensive
analysis of gene expression differences between each type of
ﬁbroblast (NCFs and ADFs) using microarrays. Many genes were
differentially expressed between NCFs and ADFs (Fig. 5A), with over
500 genes showing greater than 10-fold enhancement of expres-
sion in NCFs compared to ADFs (Supplementary Table 1). Of these,
21 genes were cardiovascular-related (Table 1). When we selected
genes that are either embryonic lethal when knocked out and/or
encode soluble factors, only VCAM-1 remained. The greater
expression of VCAM-1 in NCFs compared to ADFs was conﬁrmed by
quantitative RT-PCR and ELISA (Fig. 5BeC).
Fig. 4. (AeB) BrdU incorporation into cardiomyocytes under each culture condition as measured by FACS (N ¼ 3, **P < 0.01). (CeE) Immocytochemical identiﬁcation of car-
diomyocytes in two-chamber culture dishes on Day 1 and Day 5 by confocal microscopy; YFP (green), cTnT (red), Hoechst 33258 (blue nuclei), scale bar ¼ 500 mm. YFP(þ)/cTnT(þ)
cell number at Day 1 was set to 1.0 (N ¼ 4, **P < 0.01, *P < 0.05).
T. Iwamiya et al. / Regenerative Therapy 4 (2016) 92e102983.4. VCAM-1-dependent cardiomyocyte proliferation in co-cultures
with cardiac ﬁbroblasts
Integrin a4b1 is the principal VCAM-1 co-receptor, so we
examined integrin a4b1 expression by mESC-derived car-
diomyocytes. Indeed, almost all showed integrin a4b1 expression
(Fig. 5D), suggesting possible responsively to ﬁbroblast-derivedVCAM-1. Next, to test whether VCAM-1 contributes to cardiac
ﬁbroblast-mediated cardiomyocyte proliferation, we examined the
effects of neutralizing antibodies. After pretreatment with
neutralizing antibodies on NCFs for 30min, ﬁbroblasts were seeded
onto the upper surface of two-chamber culture dishes, while
mouse ESC-derived cardiomyocytes were seeded onto the lower
surface. Two-chamber co-culture of mESC-derived cardiomyocytes
Fig. 5. (A) Comprehensive genetic cluster analysis of ADFs and NCFs. (B) Expression levels of the VCAM-1 gene in NCFs and ADFs as measured by real-time PCR (N ¼ 3, *P < 0.05).
(C) VCAM-1 protein expression levels in conditioned medium of NCFs and ADFs as measured by enzyme-linked Immunosorbent assay (ELISA) (N ¼ 4, **P < 0.01). (D) Immuno-
cytochemical imaging of VCAM-1 co-receptor integrin a4b1 surface expression by mESC-derived cardiomyocytes; cTnT (green), integrin a4b1 (red), and Hoechst 33258 (blue
nuclei), Scale bar ¼ 500 mm. (EeF) Effect of neutralizing antibodies on cardiomyocyte number on Day 5 in two-chamber culture; YFP (green), cTnT (red), and Hoechst 33258 (blue
nuclei). Scale bar ¼ 500 mm, N ¼ 3, **P < 0.01. (GeH) Effect of VCAM-1 (soluble protein) on cardiomyocyte number on Day 5; YFP (green), cTnT (red), and Hoechst33258 (blue
nuclei). Scale bar ¼ 500 mm (N ¼ 3, *P < 0.05, **P < 0.01).
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Table 1
Cardiovascular system-related genes showing greater than 10-fold higher expres-
sion in NCFs compared with ADFs (N ¼ 3).
Gene name FCAbsolute
Chemokine (C-X-C motif) ligand 12 (Cxcl12) 89.99
Forkhead box S1 (Foxs1) 72.43
Troponin T2, cardiac (Tnnt2) 65.35
Zinc ﬁnger protein, multitype 2 (Zfpm2) 49.07
Protein tyrosine phosphatase, receptor type, B (Ptprb) 44.6
Insulin-like growth factor 1 (Igf1) 36.36
Wilms tumor 1 homolog (Wt1) 31.28
Thromboxane A2 receptor (Tbxa2r) 28.95
Collagen, type VIII, alpha 1 (Col8a1) 26.44
A disintegrin-like and metallopeptidase (reprolysin type)
with thrombospondin type 1 motif, 1 (Adamts1)
23.86
Lysyl oxidase (Lox) 23.73
c-fos induced growth factor (Figf) 23.16
Vascular cell adhesion molecule 1 (Vcam1) 21.77
Forkhead box C2 (Foxc2) 21.45
Collagen, type XI, alpha 1 (Col11a1) 20.76
Odd-skipped related 1 (Drosophila) (Osr1) 18.28
Fibroblast growth factor 18 (Fgf18) 16.95
Neuropilin 1 (Nrp1) 14.16
Meis homeobox 1 (Meis1) 12.45
Plasminogen activator, urokinase (Plau) 11.28
FCAbsolute: Absolute fold change in gene expression.
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presence of medium plus anti-VCAM-1 resulted in a substantial
inhibition of cardiomyocyte proliferation compared to two-
chamber co-culture with untreated NCFs in regular medium
(Fig. 5EeF).
Finally, we evaluated the direct (cell contact-dependent) ef-
fects of VCAM-1 on the proliferation of cardiomyocytes. One day
after seeding, cardiomyocyte monocultures were treated with
VCAM-1 until Day 5. Like the presence of NCFs, VCAM-1 treat-
ment increased the number of cardiomyocytes compared to un-
treated monocultures (Fig. 5GeH). Moreover, the number of
cardiomyocytes on Day 5 was comparable to that in co-cultures
with NCFs. These ﬁndings suggest that cardiac ﬁbroblasts
induce cardiomyocyte proliferation through expression and
release of VCAM-1.
4. Discussion
Fibroblasts participate in heart development and in the patho-
genesis of cardiovascular diseases. The presence of ﬁbroblasts is
also critical for the efﬁcient fabrication of bioengineered cardiac
tissue sheets for transplantation and in vitro studies. These effects,
which enhance cardiomyocyte proliferation and create cardiac
sheets observed in extracellular APs from all electrode sites, involve
cellcell interactions between ﬁbroblasts and surrounding car-
diomyocytes, but the signaling mechanisms remain obscure. In this
study, we demonstrate for the ﬁrst time the importance of ﬁbro-
blast source for fabricating functional bioengineered cardiac tissue
using ESC-derived cardiomyocytes. Fibroblasts from heart tissue
were superior to ﬁbroblasts from dermal tissue for fabrication of
cardiac cell sheets as NCFs-derived sheets exhibited many more
functional (beating) cardiomyocytes. This increase in functional
cardiomyocytes was due to the greater NCFs expression of VCAM-1,
which alone enhanced the cardiomyocyte proliferation.
Bioengineered cardiac tissue sheets can be used for cell-based
therapy or to establish more realistic in vitro tissue models. In
general, pluripotent stem cell-derived cardiomyocytes are used
because bioengineered cardiac tissue requires a high-yielding
source of myocyte precursors. As cardiomyocytes are responsible
for generating the contractile force of cardiac tissue, the number ofcardiomyocytes in cell sheets is thought to correlate with the
functional utility for clinical applications. In addition, efﬁcient force
generation requires the optimal spatial distribution of contractile
cells. Both of these criteria were fulﬁlled by co-culturing ESC-
derived cardiomyocytes with cardiac ﬁbroblasts; whereas, dermal
ﬁbroblast co-culture resulted in fewer cells that were aggregated in
punctuate regions of the sheet. In this study, we found that the
optimum mESC-derived cardiomyocytes to cardiac ﬁbroblast ratio
was 8:2 as previously reported [8]; therefore, efﬁcient generation of
cell sheets does not require high seeding density when using NCFs.
Furthermore cardiac ﬁbroblasts have been reported to promote the
differentiation of mouse ES cells into mature cardiomyocytes in
three-dimensional indirect co-culture condition [14]. Collectively
the presence of cardiac ﬁbroblasts might be quite important to
fabricate functional cardiac tissues via increasing number of car-
diomyocytes and promoting cardiomyocyte maturation.
Several recent studies have reported the proliferative effects of
growth factors, including granulocyte colony stimulating factor
[15], and signaling agents such as p38MAPK inhibitors [16], on
cardiomyocytes. However, few reports have identiﬁed the signaling
mechanisms mediating the interactions between cardiomyocytes
and cardiac ﬁbroblasts; mechanisms that may be exploited for
enhanced cardiomyocyte proliferation to produce superior bio-
engineered cardiac tissue. Several groups, including ours, have re-
ported that co-culture with cardiac ﬁbroblasts is indispensable for
fabricating cardiac tissue, possibly due to the insufﬁcient secretion
of extracellular matrix by cardiomyocytes alone [8,17]. In this study,
cardiac cell sheets obtained using cardiac ﬁbroblasts in co-culture
resulted in more numerous functional cardiomyocytes, suggesting
that endogenous ﬁbroblasts possess unique properties conducive
to cardiomyocyte proliferation and function. Indeed, ﬁbroblasts
from heart expressed substantially higher levels of VCAM-1 than
dermal ﬁbroblasts, resulting in faster myocyte proliferation. VCAM-
1 was reported to be also expressed on human ES/iPS cell-derived
cardiomyocytes [18]. In the present study, the increase of cell
number of mouse ES cell derived cardiomyocytes was not observed
without the existence of NCFs (Fig. 2 CeD, Figs. 3 and 4 AeB).
Although we did not examine the expression levels of VCAM-1 on
mouse ES-derived cardiomyocytes, NCFs might express more
abundant VCAM-1 than cardiomyocytes enough to induce the
proliferation of cardiomyocytes.
Cardiac ﬁbroblasts originate from multiple sources during heart
development [12]. Those normally present in the cardiac inter-
stitium and annulus ﬁbrosus are derived from the embryonic pro-
epicardium. Embryonic proepicardium-derived cells migrate to the
surface of the fetal heart and form an epicardium. Cells in the
epicardium then differentiate into cardiac ﬁbroblasts through epi-
thelialemesenchymal transition (EMT) triggered by platelet-
derived growth factor (PDGF), ﬁbroblast growth factor (FGF), and
transforming growth factor b (TGF-b) [19,20]. On the other hand,
the endothelial cells located in the atrioventicular cushion migrate
into the cardiac jelly and acquire the cardiac ﬁbroblast phenotype
through endothelialemesenchymal transition (EndMT) triggered
by TGF-b, PDGF, and Wnt [21]. In this study, we found that cardiac
ﬁbroblasts abundantly expressed VCAM-1, a ligand for a4b1
integrin expressed by cardiomyocytes. We previously reported that
soluble VCAM-1 secreted from cardiac progenitor cells showed the
cardioprotective effects through a4b1 integrin-mediated activation
of Akt, ERK and P38MAPK in cardiomyocytes. This interaction has
been reported to be also critical for heart development [22,23].
Kwee et al. [20] reported that VCAM-1 was expressed at the outer
myocardial layer, but not at the endocardial cushion at E11.5, while
a4 integrin was expressed by a single layer of epicardial cells.
Furthermore, VCAM-1-deﬁcient embryos exhibited reduced thick-
ness of the ventricular myocardium concomitant with the loss of
T. Iwamiya et al. / Regenerative Therapy 4 (2016) 92e102 101epicardial cells at E11.5 [22]. Yang et al. [21] reported the loss of
epicardium in a4 integrin-null embryos at E11.5 [23]. Therefore, the
VCAM-1/a4 integrin interaction may be the predominant signal for
formation of epicardium at the embryonic stage. In light of the
dramatic proliferative effect of cardiac ﬁbroblasts on mouse ESC-
derived cardiomyocytes through VCAM-1, we suggest that the
cardiac ﬁbroblasts used in this study may have originated primarily
from epicardium.
VCAM-1 is known to exist as both a transmembrane protein and
in a soluble form. When mESC-derived cardiomyocytes were co-
cultured with cardiac ﬁbroblasts, the number of cardiomyocytes
was increased up to 2.5 folds in 5 days (Fig. 2AeB), while the in-
crease was only about 1.5 folds when cells were co-cultured in two-
chamber culture plates allowing macromolecule diffusion but no
direct cellcell contact (Fig. 2FeG). Therefore, cardiac ﬁbroblasts
appear to induce cardiomyocyte proliferation via both direct
VCAM-1-mediated cellcell contact and by extracellular signaling
via soluble VCAM-1. Moreover, cardiomyocyte a4b1 integrin ap-
pears critical for cell adhesion, as in leukocytes and endothelial cells
[24].
The number of cardiomyocytes 1 day after culture seeding was
identical among co-cultures containing different ﬁbroblast types.
However, the number of cardiomyocytes increased substantially
after 5 days when co-cultured with cardiac ﬁbroblasts despite a
substantial loss of nonadherent (ﬂoating) cells on Day 1 in all cul-
tures, suggesting that the increased cardiomyocyte number in co-
culture with cardiac ﬁbroblasts was not due to an early increase
in cell adhesion.
Some extracellular matrix proteins have been reported to
regulate the proliferation of cardiomyocytes under special condi-
tions. Periostin is expressed in the developing and post-infarct
heart, but not in the mature healthy heart [25]. Administration
of periostin in the postnatal period induced cell cycle reentry of
differentiated cardiomyocytes through integrin av-, b1-, b3-, and
b5-mediated activation of the PI3 kinase and Akt pathways [26].
We previously reported that VCAM-1 activated Akt, Erk, and
p38MAPK in neonatal rat cardiomyocytes through a4b1 integrin
and prevented cardiomyocyte damage from oxidative stress
[26,27]. Since almost all ESC-derived cardiomyocytes expressed
a4b1 integrin under our culture conditions, activation of Akt may
be important for VCAM-1-mediated proliferation of ESC-derived
cardiomyocytes.
There are a few limitations to this study. We used cells isolated
from neonatal and adult mouse hearts as cardiac ﬁbroblasts, and
cells isolated from adult mouse dermal tissue as dermal ﬁbroblasts.
Although almost all of these cells resembled ﬁbroblasts morpho-
logically and were positive for DDR2, vimentin, and aSMA, we
cannot exclude the possibility that these populations also con-
tained other cell types. Moreover, over 500 genes were differen-
tially expressed between cardiac- and dermal-derived ﬁbroblasts;
therefore, we cannot eliminate the contribution of other factors to
cardiomyocyte proliferation. However, only VCAM-1 has been
linked to cardiovascular development and function, and a VCAM-1
antibody completely abolished the proliferative effect.
In sum, these results demonstrate that co-culture with cardiac
ﬁbroblasts improves the fabrication of functional bioengineered
cardiac tissue through VCAM-1-mediated stimulation of car-
diomyocyte proliferation. Understanding the molecular mecha-
nisms mediating cellcell signaling between cardiomyocytes and
cardiac ﬁbroblasts may provide new insights in cardiac develop-
ment and pathogenesis, and lead to improved methods for fabri-
cation of bioengineered heart tissue. Our next challenge is to
demonstrate these effects in human cells and identify the molec-
ular signaling mechanisms that trigger cardiomyocyte proliferation
after VCAM-1 stimulation by cardiac ﬁbroblasts.Acknowledgments
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